Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation

Table 7

Analyses of prognostic impact of clinicopathological, categorical variables, grouped as shown in Table 1.

	Survival^a	Recurrence^b
Number of patients	116^c	107^d
	P-values^e	P-values^e
Sex	.16	.33
Age^f	.03	.79
Extent of tumor	.91	.90
Type of osteosarcoma	.02	.06
Largest tumor diameter^f	.11	.36
Diagnostic delay^f	.30	.13
Type of surgical treatment	.16	.05
Preoperative chemotherapy	.78	.31
Histological response to chemotherapy^g	.33	.48

^aSurvival analysis based on disease-specific mortality.
^bAll kinds of recurrences, but patients with persistent, progressive disease after primary therapy have been deleted from the analyses.
^cOne patient, who did not receive preoperative chemotherapy, died from unrelated disease, and has been censored from the statistical analysis.
^dSix and 4 patients, who did not or did receive preoperative chemotherapy, respectively, had persistent, progressive disease after primary treatment, and are excluded from the statistical analysis.
^e𝑃-values as reported from log-rank tests.
^fAnalysis based on a 3-group comparison, divided on the tertiles.
^gAnalysis based on a comparison between patients (showing ≥90% versus <90% tumor necrosis, resp.).